Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)

[Background] Immune checkpoint inhibitors can be coadministered as a fixed-ratio combination (FRC) or administered as sequential infusions (ASI). Two randomized, open-label trials compared nivolumab + ipilimumab as a FRC versus ASI in patients with melanoma or renal cell carcinoma.

Detalles Bibliográficos
Autores: Menzies, Alexander M., Salman, Pamela, Frontera, Osvaldo Arén, Pook, David, Hocking, Christopher M., Zakharia, Yousef, Gurney, Howard, Gedye, Craig, Goh, Jeffrey C., Telivala, Bijoy, Grob, Jean-Jacques, Lebbé, Céleste, Cruz-Merino, Luis de la, Machet, Laurent, Neidhardt, Eve Marie, Qureshi, Anila, Hosein, Fareeda, Hamuro, Lora, Simsek, Burcin, Amin, Asim
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/400588
Acceso en línea:http://hdl.handle.net/10261/400588
https://api.elsevier.com/content/abstract/scopus_id/105009866085
Access Level:acceso abierto
Palabra clave:Immune checkpoint inhibitors
Ipilimumab
Melanoma
Nivolumab
Renal cell carcinoma
Descripción
Sumario:[Background] Immune checkpoint inhibitors can be coadministered as a fixed-ratio combination (FRC) or administered as sequential infusions (ASI). Two randomized, open-label trials compared nivolumab + ipilimumab as a FRC versus ASI in patients with melanoma or renal cell carcinoma.

Similares en LA Referencia